Biopharmaceutical researchers are focusing on novel platforms to quickly develop bispecific antibody (BsAb) therapies for treating complex diseases such as cancer. BsAb therapies offer several advantages because they are designed to bind two unique epitopes. In this report, Bill Lundberg, president and chief executive officer at Merus, describes his company‚Äôs efficient approach to developing BsAbs using ‚Äúcommon light chain‚ÄĚ technology and other proprietary strategies. Lundberg also addresses the company‚Äôs approach to typical BsAb development and manufacturing challenges.
Fill out the form below to read the eBook now.